Plain-English translation of NCT07693426 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called Efsubaglutide Alfa to see if it can safely help teenagers ages 12–17 with obesity lose weight. The study will give some teenagers the medication and others a placebo (a dummy injection with no active drug) once a week for 12 weeks. Researchers will watch closely to see how safe the medication is and how well it works.
Right now, there are no approved medications to help teenagers manage obesity, even though teen obesity is becoming more common and affecting both physical and mental health. This trial exists to find a treatment option for young people who haven't had success with diet and exercise alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will come for visits over 12 weeks and receive an injection once a week using a pre-filled pen (similar to an EpiPen). You'll be randomly assigned to receive either the new medication or a placebo. Throughout the study, doctors will check your safety by doing blood tests, checking your vital signs, and asking about any side effects you experience. You'll also need to keep up with healthy eating and exercise as you've been doing.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
China